Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Akebia Therapeutics Ownership Summary


Akebia Therapeutics is owned by 45.98% institutional investors, 3.56% insiders, and 50.46% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.80% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.96% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkebia Therapeutics45.98%3.56%50.46%
SectorHealthcare Stocks 486.50%11.08%-397.59%
IndustryBiotech Stocks 304.14%11.08%-215.23%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de18.37M7.80%$66.88M
Blackrock11.64M5.68%$11.87M
Vanguard group10.88M5.17%$20.68M
State street6.30M3.00%$11.98M
Alerce investment management5.75M2.73%$10.92M
Geode capital management4.80M2.28%$9.11M
Renaissance3.82M1.82%$7.26M
Bioimpact capital2.89M1.23%$10.52M
Jacobs levy equity management2.09M1.02%$2.14M
Nantahala capital management2.00M0.85%$7.28M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alerce investment management5.75M19.23%$10.92M
Great point partners1.99M4.70%$7.23M
Bioimpact capital2.89M1.82%$10.52M
Affinity asset advisors1.95M0.97%$7.10M
Nantahala capital management2.00M0.29%$7.28M
Orchard capital management53.51K0.22%$194.78K
Diametric capital, lp57.53K0.11%$209.42K
Entrypoint capital41.00K0.07%$149.22K
Wealth effects34.50K0.05%$125.58K
Alphamark advisors38.46K0.03%$73.00K

Top Buyers

HolderShares% AssetsChange
Blackrock11.64M0.00%9.10M
Blackrock funding, inc. /de18.37M0.00%3.04M
Bioimpact capital2.89M1.82%2.89M
State street6.30M0.00%2.87M
Acadian asset management1.35M0.01%1.35M

Top Sellers

HolderShares% AssetsChange
Great point partners1.99M4.70%-2.99M
Aigh capital management---2.92M
Monashee investment management---1.50M
Balyasny asset management9.15K0.00%-1.24M
Axa---627.89K

New Positions

HolderShares% AssetsChangeValue
Bioimpact capital2.89M1.82%2.89M$10.52M
Acadian asset management1.35M0.01%1.35M$4.91M
Exoduspoint capital management, lp289.53K0.01%289.53K$1.05M
Walleye capital214.82K0.00%214.82K$781.93K
Alps advisors141.66K0.00%141.66K$515.66K

Sold Out

HolderChange
Northwestern mutual wealth management-5.00
Capital performance advisors llp-68.00
Hexagon capital partners-186.00
Laurel wealth advisors-229.00
Redwood wealth management group-300.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20251628.72%108,281,33413.45%452.80%11119.35%23-11.54%
Mar 31, 202515019.05%95,500,61040.77%403.90%9434.29%2722.73%
Dec 31, 20241244.20%67,787,36714.05%324.04%7018.64%22-15.38%
Sep 30, 20241189.26%59,390,7035.52%283.74%599.26%268.33%
Jun 30, 2024108-14.29%56,234,084-1.41%273.04%53-27.40%24-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv7.79M2.96%-172.84K
Vanguard US Total Market Shares ETF5.95M2.52%-
iShares Russell 2000 ETF5.93M2.26%-112.77K
SPDR® S&P Biotech ETF3.08M1.17%76.01K
Vanguard Institutional Extnd Mkt Idx Tr2.59M0.99%-1.16M
Fidelity Small Cap Index2.19M0.83%3.43K
Nuveen Quant Small Cap Equity R62.07M0.79%-41.26K
Foord Global Equity (Lux) A1.99M0.76%1.99M
iShares Russell 2000 Value ETF1.95M0.74%1.45K
Foord Global Equity Class B1.83M0.70%1.83M

Recent Insider Transactions


DateNameRoleActivityValue
Jun 30, 2025Ostrowski Erik SVP, CFO, CBO & TreasurerSell$151.62K
Jun 09, 2025Malabre Richard C SVP, Chief Accounting OfficerSell$60.15K
Jun 04, 2025Malabre Richard C SVP, Chief Accounting OfficerSell$47.07K
Mar 03, 2025Butler John P. CEO and PresidentSell$84.93K
Mar 03, 2025Burke Steven Keith SVP, Chief Medical OfficerSell$13.07K

Insider Transactions Trends


DateBuySell
2025 Q2-3
2025 Q1-8
2024 Q2-2
2024 Q1-10
2023 Q3-1

AKBA Ownership FAQ


Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 45.98%, followed by 3.56% insiders and 50.46% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 304.14%, which Akebia Therapeutics falls below.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock funding, inc. /de (18.37M shares, 7.80%), Blackrock (11.64M shares, 5.68%), and Vanguard group (10.88M shares, 5.17%). Together, they hold 18.66% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.23% of its assets in 5.75M Akebia Therapeutics shares, valued at 10.92M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akebia Therapeutics shares, with 2.96% of its total shares outstanding invested in 7.79M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools